AZ304

CAS No. 942507-42-8

AZ304( AZ 304 | AZ-304 )

Catalog No. M16746 CAS No. 942507-42-8

AZ304 is a novel potent, dual BRAF inhibitor targeting the kinase domains of wild type BRAF, V600E mutant BRAF and wild type CRAF with IC50 of 79 nM, 38 nM and 68 nM, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 42 In Stock
10MG 61 In Stock
25MG 113 In Stock
50MG 186 In Stock
100MG 332 In Stock
200MG 498 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    AZ304
  • Note
    Research use only, not for human use.
  • Brief Description
    AZ304 is a novel potent, dual BRAF inhibitor targeting the kinase domains of wild type BRAF, V600E mutant BRAF and wild type CRAF with IC50 of 79 nM, 38 nM and 68 nM, respectively.
  • Description
    AZ304 is a novel potent, dual BRAF inhibitor targeting the kinase domains of wild type BRAF, V600E mutant BRAF and wild type CRAF with IC50 of 79 nM, 38 nM and 68 nM, respectively; also potentlt inhibits p38 and CSF1R with IC50 of 6 and 35 nM, has no activity for MAP3K7, CSK, IGF1R, EGFR, FGFR, CDK2, CDK4, JAK2, SRC (IC50>5 uM); potently reduces p-ERK with mean EC50 of 65 nM in the V600E mutant BRAF containing melanoma cell line A375, EC50 of 60 nM in wild type BRAF melanoma cell line SK-MEL-31; inhibits cell proliferation in mutant BRAF, wt BRAF/RAS and mutant RAS with IC50 of 0.08-7.72 uM, 0.43-11.7 uM 0.9-16.66 uM, respectively; Cetuximab enhances the potency of AZ304 independently of BRAF mutational status in vivo.
  • In Vitro
    AZ304 (1 nM-100 μM) potently reduces ERK phosphorylation (p-ERK), with a mean EC50 of 65 nM in the V600E mutant BRAF containing melanoma cell line A375, and EC50s of 52 nM, 60 nM in the wild type BRAF melanoma cell line SK-MEL-31 with and without EGF.AZ304 also potently inhibits p-p38 in both BRAF genetic statuses cell lines.AZ304 (0, 0.1, 1, 10, 100 μM, 48 and 72 hours) dose-dependently inhibits the growth of RKO, HT-29, DiFi, and Caco-2, with GI50s of 4.539 μM, 3.896 μM, 4.987 μM, 1.763 μM (48 hours) and 0.5032 μM, 0.3887 μM, 0.6354 μM, 0.3772 μM (72 hours), respectively.AZ304 (2 μM, 36 and 48 hours) decreases BRAF, p-ERK, p-AKT and p-mTOR levels, increases p-EGFR in both BRAF V600E mutant and BRAF wild type cells. AZ304 down-regulates p-EGFR, inhibits p-ERK, more potently suppresses BRAF, ERK, AKT and mTOR signalling pathways in combination with C225. Cell Proliferation Assay Cell Line:RKO, HT-29, DiFi, Caco-2 cells Concentration:0, 0.1, 1, 10, 100 μM Incubation Time:48, 72 hours Result:Dose-dependently inhibited the growth of V600E mutant BRAF cell lines (RKO, HT-29) and wild-type BRAF cell lines (DiFi, Caco-2).
  • In Vivo
    ——
  • Synonyms
    AZ 304 | AZ-304
  • Pathway
    MAPK/ERK Signaling
  • Target
    Raf
  • Recptor
    B-RAFV600E|B-RAF|C-RAF|p38|CSF1R
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    942507-42-8
  • Formula Weight
    451.53
  • Molecular Formula
    C27H25N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 85 mg/mL; Ethanol: 4 mg/mL; Water: Insoluble ( < 1 mg/ml refers to the product slightly soluble or insoluble )
  • SMILES
    O=C(NC1=CC=C(C)C(NC2=C3C=CC(OC)=CC3=NC=N2)=C1)C4=CC=CC(C(C)(C#N)C)=C4
  • Chemical Name
    3-(2-cyanopropan-2-yl)-N-(3-((7-methoxyquinazolin-4-yl)amino)-4-methylphenyl)benzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ma R, et al. Br J Cancer. 2018 May 14. doi: 10.1038/s41416-018-0086-x.
molnova catalog
related products
  • MCP110

    MCP110 is a potent Ras/Raf-1 interaction inhibitor.

  • Sorafenib-d3

    Sorafenib-d3 is a deuterium-labeled Sorafenib which is a multikinase inhibitor(IC50s: 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively).

  • SB408124

    SB408124 is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and 27 nM in both whole cell and membrane, respectively, exhibits 50-fold selectivity over OX2 receptor.